• Home
  • Agric
  • Sci & Tech
  • Health
  • Environment
  • Hausa News
  • More
    • Business/Banking & Finance
    • POLITICS
    • Entertainments & Sports
    • International
    • Investigation
    • Law & Human Rights
    • Africa
    • ACCOUNTABILITY/CORRUPTION
    • Hassan Gimba
    • Column
    • Prof. Jibrin Ibrahim
    • Prof. M.K. Othman
    • Defense/Security
    • Education
    • Energy/Electricity
    • Entertainment/Arts & Sports
    • Society and Lifestyle
    • Food & Agriculture
    • Health & Healthy Living
    • International News
    • Interviews
    • Investigation/Fact-Check
    • LAW & HUMAN RIGHTS
    • Oil & Gas/Mineral Resources
    • PRESS FREEDOM/JOURNALISM/PR
    • General News
    • Presidency
  • About Us
    • Contact Us
    • Board Of Advisory
    • Privacy Policy
    • Ethics Policy
    • Teamwork And Collaboration Policy
    • Fact-Checking Policy
    • Advertising
  • Media OutReach Newswire
    • Wire News
  • The Stories
Facebook Twitter Instagram
Trending
  • KSCHMA confers ambassadorial title on Madobi district head
  • NEPC urges soybean farmers to embrace value chain
  • Nigeria’s inflation projected to rise marginally to 15.95% in June
  • LASCAFAN to train 500 youths in fish farming by end of 2026
  • SEDC signs MoU with Abia for agro development programme
  • SMEDAN to equip rice clusters with modern milling machines
  • A B Mahmoud and the three stages of public service, by Prof. Jibrin Ibrahim
  • Audiologist warns against unsafe ear cleaning
Facebook Twitter Instagram YouTube
AsheNewsAsheNews
  • Home
  • Agric

    NEPC urges soybean farmers to embrace value chain

    July 3, 2026

    Nigeria’s inflation projected to rise marginally to 15.95% in June

    July 3, 2026

    LASCAFAN to train 500 youths in fish farming by end of 2026

    July 3, 2026

    SEDC signs MoU with Abia for agro development programme

    July 3, 2026

    SMEDAN to equip rice clusters with modern milling machines

    July 3, 2026
  • Sci & Tech

    FG reaffirms commitment to national digital postcode system

    July 2, 2026

    Google cloud: Johannesburg region to generate $90.6bn, 315,000 jobs by 2030

    July 2, 2026

    Nigerian marketplace 2Clicks hits 100k milestone

    July 2, 2026

    NCC urges accelerated FTTH deployment to achieve $1tn economy

    July 1, 2026

    WhatsApp rolls out username reservations for better privacy

    June 29, 2026
  • Health

    KSCHMA confers ambassadorial title on Madobi district head

    July 3, 2026

    Audiologist warns against unsafe ear cleaning

    July 3, 2026

    International clinical trial for bundibugyo virus treatment begins in DRC

    July 3, 2026

    CCD holds workshop to promote disability-inclusive climate action in Abia

    July 2, 2026

    Nigeria reports 80% readiness for Ebola risk communication, community engagement

    July 2, 2026
  • Environment

    Sokoto strengthens flood preparedness for 2026 season

    July 2, 2026

    LASEPA seals 10 establishments in Lagos for environmental violations

    July 2, 2026

    Anambra residents appeal for urgent help over worsening erosion

    July 2, 2026

    Climate awareness: Shiroro schools compete in PCR Ambassadors’ maiden sustainability contest

    July 1, 2026

    FCTA begins 2025 promotion exams for over 13,000 civil servants

    July 1, 2026
  • Hausa News

    UNA signs MoU to launch air Bissau in Guinea-Bissau

    June 15, 2026

    Otti plans 250-room 5-star hotel in Umuahia

    April 11, 2026

    Anti-quackery task force seals 4 fake hospitals in Rivers

    August 29, 2025

    [BIDIYO] Yadda na lashe gasa ta duniya a fannin Ingilishi – Rukayya ‘yar shekara 17

    August 6, 2025

    A Saka Baki, A Sasanta Saɓani Tsakanin ‘Yanjarida Da Liman, Daga Muhammad Sajo

    May 21, 2025
  • More
    1. Business/Banking & Finance
    2. POLITICS
    3. Entertainments & Sports
    4. International
    5. Investigation
    6. Law & Human Rights
    7. Africa
    8. ACCOUNTABILITY/CORRUPTION
    9. Hassan Gimba
    10. Column
    11. Prof. Jibrin Ibrahim
    12. Prof. M.K. Othman
    13. Defense/Security
    14. Education
    15. Energy/Electricity
    16. Entertainment/Arts & Sports
    17. Society and Lifestyle
    18. Food & Agriculture
    19. Health & Healthy Living
    20. International News
    21. Interviews
    22. Investigation/Fact-Check
    23. LAW & HUMAN RIGHTS
    24. Oil & Gas/Mineral Resources
    25. PRESS FREEDOM/JOURNALISM/PR
    26. General News
    27. Presidency
    Featured
    Recent

    KSCHMA confers ambassadorial title on Madobi district head

    July 3, 2026

    NEPC urges soybean farmers to embrace value chain

    July 3, 2026

    Nigeria’s inflation projected to rise marginally to 15.95% in June

    July 3, 2026
  • About Us
    1. Contact Us
    2. Board Of Advisory
    3. Privacy Policy
    4. Ethics Policy
    5. Teamwork And Collaboration Policy
    6. Fact-Checking Policy
    7. Advertising
    Featured
    Recent

    KSCHMA confers ambassadorial title on Madobi district head

    July 3, 2026

    NEPC urges soybean farmers to embrace value chain

    July 3, 2026

    Nigeria’s inflation projected to rise marginally to 15.95% in June

    July 3, 2026
  • Media OutReach Newswire
    • Wire News
  • The Stories
AsheNewsAsheNews
Home»Health & Healthy Living»Migraine-preventing drug significantly reduces rebound headache occurrence
Health & Healthy Living

Migraine-preventing drug significantly reduces rebound headache occurrence

Abdallah el-KurebeBy Abdallah el-KurebeOctober 7, 2024No Comments5 Mins Read
Migraine-prevention drug
Share
Facebook Twitter LinkedIn Pinterest Email

A drug used in the prevention of migraine may also help reduce so-called rebound headaches, according to a new review of data from a randomized, double-blind, placebo-controlled migraine trial.

  • A preventive drug for migraine proves effective at avoiding ‘rebound’ headaches in a new study.
  • The medication is sufficiently effective that people taking it have less need for additional pain meds that can cause rebound headaches.
  • The drug, atogepant, relaxes the blood vessel at which a migraine attack begins, preventing it from becoming too large and irritating the meninges at the bottom of the skull, causing the throbbing pain associated with migraine.

When the drug, atogepant, is taken every day, migraine-related pain can be alleviated, decreasing the need for additional painkillers, believed to be the source of rebound headaches.

The study was led by headache specialist Peter J. Goadsby, MBBS, MD, PhD of King’s College London in the United Kingdom, and a member of the American Academy of Neurology. Its findings appear in the journal Neurology.

Atogepant reduces rebound headaches by 50%

There were 755 participants in the trial, each of whom experienced chronic migraine. Each had at least 15 days of headaches per month, with at least eight qualifying as migraine.

Out of the total group, 66% were overusing pain medications, which often occurs with people attempting to get rid of their headaches.

They were resorting to simple analgesics — such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or acetaminophen — for at least 15 days each month. Some took triptans or ergot alkaloids for at least 10 days. Some took a combination of both for at least 10 days in a month.

The trial began with a 4-week screening/baseline period.

At the beginning of the trial, participants averaged 18 to 19 migraine days per month and were taking medications for pain for 15 to 16 days.

Next, individuals were randomly assigned to take 30 milligrams (mg) of atogepant twice daily, 60 mg of atogepant once each day, or a placebo for 12 weeks. During this period, they were monitored for the frequency of their painkiller use.

Participants who took atogepant took painkillers on fewer days during the trial. Additionally, a higher proportion of participants taking atogepant had a 50% or greater reduction in rebound headaches per month.

What causes migraine and why it’s challenging to treat

In general, said Goadsby, “[m]igraine is an inherited brain disease whose attacks are triggered by changes in the brain and changes in the external environment.”

“We know the path of physiology, but we don’t know what causes a migraine because there are different triggers for different people,” Clifford Segil, DO, a neurologist at Providence Saint John’s Health Center in Santa Monica, CA, who was not involved in the study, told Medical News Today.

“For example,” he said, “many people with red wines versus white wines get it. Many people with cheeses get it. Caffeine both triggers headaches and treats headaches. So we’re still not entirely sure what causes the headaches.”

Modern, pharmaceutical therapies for migraine attacks fall into two camps: preventive and rescue. Atogepant is strictly a preventive drug, though it is closely related to two other drugs — ubrogepant and rimegepant — that are rescue and combination preventive/rescue drugs, respectively.

“Atogepant is a migraine preventive,” said Goadsby. “By taking it every day, the patient has less migraine and a much-reduced need for acute treatments such as painkillers. In effect, it stops the attack before it starts.”

The drug “relaxes the [involved] blood vessel, which makes it get narrower and not as wide, and when it’s not as wide, it feels better,” Segil explained.

What are rebound headaches?

Goadsby also explained rebound headaches and why they occur. He told us that:

“Rebound headache occurs when a medicine taken to relieve an attack wears off and the headache returns. Say you have a migraine that is going to last 2 days. If you take a medicine on day one that lasts for 24 hours, then the headache will return (rebound) the next day, and you need to take another treatment.”

“A big problem with migraines is that people take too much medication, so we can get what’s called a ‘medication overuse headache’ or a ‘rebound’ headache. The easiest example is when someone has some pain, and they take a Motrin, Advil, or Alleve [or some other] NSAID every day,” Segil explained.

Goadsby also cautioned that some pain medications, such as NSAIDs, taken too often, can result in stomach ulcers and other assaults on the digestive tract.

“Taking pain medicines can, paradoxically, increase the number of migraine days the patient has so-called medication overuse headache, so taking fewer pain meds stops that happening,” he said.

According to Segil, overuse of pain meds may never give a migraine attack a chance to go away.

Migraine symptoms: What to know

A migraine is a severe headache that is classically characterized by throbbing pain, sometimes covering half the head.

It may be accompanied by an uncomfortable sensitivity to bright lights and loud noises — photophobia or phonophobia, respectively — with or without blurry vision or a visual aura, a difficult-to-describe symptom in which vision becomes prismatic.

“Generally speaking, when people get migraines, there is a blood vessel between the brain and the skull in your meninges, and when the blood vessel gets too big, it dilates. It tugs on the meninges [which is] the shock absorber of the brain. That usually causes the throbbing pain,” Segil explained.

“After that, there’s irritation of the cortex of the brain, and a wave of electricity called cortical spreading depression, and that’s usually the radiating pain,” he detailed.

By Robby Berman, MedicalNewsToday

Migraine-preventing drug
Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Abdallah el-Kurebe
  • Website
  • Facebook
  • Twitter
  • LinkedIn

Related Posts

KSCHMA confers ambassadorial title on Madobi district head

July 3, 2026

Audiologist warns against unsafe ear cleaning

July 3, 2026

International clinical trial for bundibugyo virus treatment begins in DRC

July 3, 2026

Leave A Reply Cancel Reply

KSCHMA confers ambassadorial title on Madobi district head

July 3, 2026

NEPC urges soybean farmers to embrace value chain

July 3, 2026

Nigeria’s inflation projected to rise marginally to 15.95% in June

July 3, 2026

LASCAFAN to train 500 youths in fish farming by end of 2026

July 3, 2026
About Us
About Us

ASHENEWS (AsheNewsDaily.com), published by PenPlus Online Media Publishers, is an independent online newspaper. We report development news, especially on Agriculture, Science, Health and Environment as they affect the under-reported rural and urban poor.

We also conduct investigations, especially in the areas of ASHE, as well as other general interests, including corruption, human rights, illicit financial flows, and politics.

Contact Info:
  • 1st floor, Dogon Daji House, No. 5, Maiduguri Road, Sokoto
  • +234(0)7031140009
  • ashenewsdaily@gmail.com
Facebook Twitter Instagram Pinterest
© 2026 All Rights Reserved. ASHENEWS Daily Designed & Managed By DeedsTech

Type above and press Enter to search. Press Esc to cancel.